SULFADIAZINE SODIUM INJECTION MARKET ANALYSIS

Sulfadiazine Sodium Injection Market, by Product Type (20mg/mL, 40mg/mL, others), by Patient Type (Human, and Animal), By Indication (Toxoplasmosis, Acute Otitis Media (AOM), Chancroid, Chlamydial Infections, Haemophilus Influenzae Infections, Malaria, Neisseria Meningitides Infections, Plague, Urinary Tract Infections), by End User (Hospitals, Clinics, Medical Centers, and Veterinary), and by Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Dec 2024
Code : CMI2313
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Sulfadiazine Sodium Injection Market– Restraint

Over the years, bacterial pathogens acquired resistance to sulfonamide class of antibiotics, due to mutations in pre-existing DNA, or by acquisition of antibiotic resistance genes (ARGs), which is expected to hinder growth of the sulfachloropyridazine sodium market. For instance, according to Centers for Disease Control and Prevention (CDC), in the U.S. doctors and emergency departments, prescribe at least 47 million antibiotic prescriptions each year, which are unnecessary. These are creating spread of antibiotics resistance, which might lead to severe consequences.

SULFADIAZINE SODIUM INJECTION MARKET ANALYSIS

Market Challenges And Opportunities

Sulfadiazine Sodium Injection Market Report Snapshots

EXISTING CLIENTELE